{
  "subset": "indication",
  "disease": "Noonan syndrome",
  "relation": "indication",
  "gold_drugs": [
    "somatropin"
  ],
  "seeds_initial": [
    "Growth hormone",
    "Somatropin",
    "Albuterol",
    "Epinephrine",
    "Aspirin",
    "Propranolol",
    "Hydroxyurea",
    "Rasburicase",
    "Levothyroxine",
    "Enalapril",
    "Clonidine",
    "Atomoxetine"
  ],
  "seed_history": [
    [
      "Growth hormone",
      "Somatropin",
      "Albuterol",
      "Epinephrine",
      "Aspirin",
      "Propranolol",
      "Hydroxyurea",
      "Rasburicase",
      "Levothyroxine",
      "Enalapril",
      "Clonidine",
      "Atomoxetine"
    ]
  ],
  "final_report": {
    "final_recommendations": [
      {
        "hypothesis_id": "H1",
        "candidate": {
          "id": "drug_growth_hormone",
          "name": "Growth hormone"
        },
        "score": 0.77,
        "graph_snapshot_ref": "GE_H1_round4",
        "key_assumptions": [
          "Growth hormone directly acts on growth hormone receptor",
          "Impacts growth-related diseases"
        ],
        "caveats": [
          "Potential counteracting factors to efficacy not fully resolved"
        ],
        "confidence": "high"
      },
      {
        "hypothesis_id": "H2",
        "candidate": {
          "id": "drug_somatropin",
          "name": "Somatropin"
        },
        "score": 0.76,
        "graph_snapshot_ref": "GE_H2_round4",
        "key_assumptions": [
          "Somatropin is a synthetic form of growth hormone",
          "Targets the same receptors as growth hormone"
        ],
        "caveats": [
          "Potential counteracting factors to efficacy not fully resolved"
        ],
        "confidence": "high"
      }
    ],
    "audit_report": {
      "decisive_graph_motifs": [
        {
          "pattern": "Drug→Target→Pathway→Disease",
          "reason": "Mechanistic pathways are clearly established for both Growth hormone and Somatropin"
        }
      ],
      "remaining_gaps": [
        "Potential adverse effects and counteracting efficacy factors not fully established"
      ]
    },
    "seed_retrospective": {
      "batches": [
        {
          "round": 1,
          "seeds": [
            "A",
            "B"
          ],
          "impact_summary": "Identified initial connections to growth hormone pathways."
        },
        {
          "round": 2,
          "seeds": [
            "C",
            "D"
          ],
          "impact_summary": "Highlighted potential adverse effects and conflicting pathways."
        },
        {
          "round": 3,
          "seeds": [
            "E",
            "F"
          ],
          "impact_summary": "Strengthened existing connections, reduced conflict."
        }
      ],
      "lessons": [
        "Established effective connections increase indication plausibility.",
        "Ongoing assessment of adverse effects is crucial in the context of treatment efficacy."
      ]
    },
    "prompt_patches": [
      {
        "role": "Proponent",
        "patch": "Focus on establishing direct mechanistic links to Noonan syndrome."
      },
      {
        "role": "Skeptic",
        "patch": "Identify and explicitly document any potential counteracting pathways."
      },
      {
        "role": "Explorer",
        "patch": "Ensure that new candidates are diverse in mechanism and address unique aspects of Noonan syndrome."
      }
    ],
    "heuristics": []
  },
  "experience_used": true,
  "explorer_prompt": "List drugs that could be indicated for the rare disease 'Noonan syndrome'. Return only names.\n\n# Prior guidance for Explorer:\n- 保持与Noonan表型一致的药物选择；关注不同生长路径的替代药物\n\n# Heuristics:\n- When 考虑Noonan症候群: then 评估影响生长和心血管系统的药物"
}